Holen Sie sich die Stockscreener-App
275.21
2.06%
5.56
Handel nachbörslich:
275.21
Schlusskurs vom Vortag:
$269.65
Offen:
$270.94
24-Stunden-Volumen:
260.33K
Relative Volume:
1.15
Marktkapitalisierung:
$7.43B
Einnahmen:
$2.58B
Nettoeinkommen (Verlust:
$-778.69M
KGV:
-10.07
EPS:
-27.33
Netto-Cashflow:
$223.75M
1W Leistung:
+1.22%
1M Leistung:
-8.04%
6M Leistung:
-7.21%
1J Leistung:
-0.35%
1-Tages-Spanne:
$268.00
$275.71
1-Wochen-Bereich:
$267.13
$275.99
52-Wochen-Spanne:
$211.43
$343.12
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Firmenname
Bio Rad Laboratories Inc
Sektor
Branche
Telefon
(510) 724-7000
Adresse
1000 ALFRED NOBEL DRIVE, HERCULES
Compare BIO vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
275.21 | 7.28B | 2.58B | -778.69M | 223.75M | -27.33 |
|
ABT
Abbott Laboratories
|
116.26 | 199.55B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
386.06 | 146.96B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
97.03 | 123.91B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
75.75 | 109.04B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
85.90 | 48.40B | 6.07B | 1.06B | 799.60M | 1.8527 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-04-03 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-12-07 | Eingeleitet | UBS | Buy |
| 2023-06-16 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-01-28 | Bestätigt | Citigroup | Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2018-10-17 | Eingeleitet | Goldman | Buy |
| 2018-09-20 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2018-02-16 | Herabstufung | CL King | Buy → Neutral |
| 2017-07-13 | Eingeleitet | Wells Fargo | Outperform |
| 2017-06-28 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Hold |
| 2016-10-13 | Eingeleitet | CL King | Buy |
| 2015-05-06 | Bestätigt | Jefferies | Buy |
| 2009-12-18 | Eingeleitet | Maxim Group | Buy |
| 2009-11-06 | Eingeleitet | Jefferies & Co | Buy |
| 2009-07-17 | Eingeleitet | Soleil | Buy |
| 2007-09-26 | Eingeleitet | Banc of America Sec | Buy |
| 2007-02-23 | Herabstufung | Robert W. Baird | Outperform → Neutral |
Alle ansehen
Bio Rad Laboratories Inc Aktie (BIO) Neueste Nachrichten
Bio-Rad Laboratories Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
A Look At Bio Rad Laboratories (BIO) Valuation After Recent Share Price Weakness - simplywall.st
(BIO) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Molecular Biology Analyzers Market Set to Boom by 2033: - openPR.com
Microfluidics Research Report 2026-2035: A $20.73 Billion - GlobeNewswire
Microfluidics Research Report 2026-2035: A $20.73 Billion Market by 2030 with Thermo Fisher Scientific, PerkinElmer, Dolomite, Agilent Technologies, Bio-Rad Laboratories, and Fluidigm Leading - Yahoo Finance
Weekly Earnings: What is the long term forecast for Bio Rad Laboratories Inc stockJuly 2025 Reactions & High Win Rate Trade Alerts - baoquankhu1.vn
International Markets and Bio-Rad (BIO): A Deep Dive for Investors - Yahoo Finance
Blood Grouping Reagents Market Top Key Players -Grifols, Roche, - openPR.com
Hemocytometer Market Is Going to Boom Rapidly With Top Key - openPR.com
4 Undervalued Life Sciences Tools & Services Stocks for Thursday, February 19 - AAII
Bio-Rad Updates Investors on Sartorius Strategic Investment Metrics - TipRanks
Bio-Rad Laboratories, Inc. (BIO) achieves modest revenue growth and robust free cash flow growth - MSN
Bio-Rad Laboratories, Inc. (BIO) Achieves Modest Revenue Growth and Robust Free Cash Flow Growth - Finviz
Risk Hedge: Is RBOT still a buy after recent gains2025 Institutional Moves & Stock Timing and Entry Methods - baoquankhu1.vn
Bio-Rad's Q4 Earnings Miss Estimates, Revenues Surpass, Stock Down - Yahoo Finance
Protein Engineering Market to Grow at 15.6% CAGR from 2025 - openPR.com
Protein Engineering Market Is Going to Boom Rapidly With Top Key - openPR.com
Bio-Rad's Timing for Revenue Growth Recovery Remains Uncertain - Morningstar
United States Molecular Quality Controls Market to Reach CAGR - openPR.com
Dematic Automation Solution drives precision and productivity for Bio-Rad Singapore - mhdsupplychain.com.au
MSN Money - MSN
Is It Time To Reassess Bio-Rad Laboratories (BIO) After Multi Year Share Price Weakness - Yahoo Finance
Assessing Bio-Rad Laboratories (BIO) Valuation After Prolonged Share Price Weakness - Yahoo Finance
Bio-Rad Laboratories (BIO) Returns To Profitability With Diagnostics Rebound – Is The Turnaround Durable? - Yahoo Finance
Bio-Rad Laboratories Q4 2025 sales up 9% to USD 693.2M - Medical Buyer
Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2025 earnings call transcript - MSN
Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2025 Earnings Call Transcript - Insider Monkey
Bio-Rad Laboratories (NYSE:BIO) Lowered to "Hold" Rating by Wall Street Zen - MarketBeat
Beyond the Balance Sheet: What SWOT Reveals About Bio-Rad Labora - GuruFocus
Will Bio Rad Laboratories Inc. benefit from geopolitical trendsWeekly Profit Report & Low Risk Entry Point Tips - mfd.ru
Bio-Rad Q4 2025 slides reveal modest growth amid segment divergence and strategic shifts - Investing.com Nigeria
Bio-Rad Laboratories (NYSE:BIO.B) Shares Gap DownHere's What Happened - MarketBeat
Bio-Rad Laboratories Inc (BIO) Shares Down 11.17% on Feb 13 - GuruFocus
Oversold Conditions For Bio-Rad Laboratories (BIO) - Nasdaq
UBS Adjusts Price Target on Bio-Rad Laboratories to $335 From $350, Maintains Buy Rating - marketscreener.com
Bio-Rad Laboratories (BIO) Shares Cross Below 200 DMA - Nasdaq
Bio-Rad Laboratories (NYSE:BIO) Shares Gap Down After Earnings Miss - MarketBeat
Bio-Rad Laboratories, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Pinterest Posts Downbeat Results, Joins DraftKings, Toast, Expedia And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
S&P 500 Futures Drop In Premarket Trading; Pinterest, Bio-Rad Labs A Lag - 富途牛牛
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
BIO-RAD LABORATORIES, INC. SEC 10-K Report - TradingView
Bio-Rad (BIO) Reports Q4 Revenue Growth and Strategic Initiatives - GuruFocus
Bio-Rad Laboratories, Inc. $BIO Holdings Lifted by Envestnet Asset Management Inc. - MarketBeat
Bio-Rad outlines 2026 margin expansion and 0.5%-1.5% revenue growth guidance amid operational improvements - MSN
Bio-Rad Laboratories Q4 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Bio-Rad Labs Q4 2025 misses EPS expectations - Investing.com Australia
Bio-Rad Laboratories Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Bio-Rad Labs Q4 2025 misses EPS expectations By Investing.com - Investing.com South Africa
Bio-Rad Laboratories (NYSE:BIO.B) Posts Quarterly Earnings Results - MarketBeat
Finanzdaten der Bio Rad Laboratories Inc-Aktie (BIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.14%
0.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):